Science Bro
@Science_Bro1
Followers
75
Following
68
Media
1
Statuses
63
Postdoc biomedical researcher. Passionate about bringing scientists towards a decentralised future.
Australia
Joined January 2025
Giving infectious disease research a break, as promised by the MAHA agenda. Let's break down what exactly this Executive Order is *really* saying. Fortunately, I speak fluent anti-vax grifterese & can translate. https://t.co/3TjI4SZID2
whitehouse.gov
By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.
230
3K
13K
Who does the speculative aspect benefit? At the moment I’m mainly seeing it benefit crypto speculators. Is it really attracting many scientists? Are they staying due to holding the depreciating assets or for the vision?
0
0
1
My vision for #DeSci is bringing scientists into a decentralised community where their funding source won’t drop 90% in 4 weeks. Can people tag me in projects that are using tokenomics ethically and appropriately?
9
4
32
Want a successful #DeSci DAO? 1. Set a clear, achievable mission 2. Back projects with short-term wins 3. Build a product that helps other DeSci projects 4. Use that success to expand into academia & biotech. Then, scale up to tackle bigger challenges in science.
1
0
5
Science isn’t broken, but this initiative is fantastic. I’ll be applying.
We've got news! We're launching DeSci Edu—an 8-week program powered by Molecule & @bioprotocol to train the next generation of decentralized science innovators. If you want to start your career in DeSci, this is for you. 🧵👇
1
0
5
#DeSci needs to start with practical, achievable goals. I keep seeing takes like “NIH collapse? Good! DeSci will step in!” C’mon, people. The NIH's annual budget is $48B. The entire DeSci market cap is ~$1B. The biggest project? $250M. Let’s build first. 🚀
12
3
57
This is the first in a series from an academic’s perspective on DeSci. Next up: the opportunities of AI agents in academia and DAO collaborations with academic start-up incubators. #DAO #DeSci
Dr. Che Stafford, Research Scientist and Alpha Leader, @Blockcircle (@Science_Bro1) and I wrote this article on Why Early-Stage DeSci DAOs Should Avoid Funding Research First https://t.co/kKYDuqtSGX
0
2
11
One of many #DESCI projects we have been monitoring and liking in @Blockcircle is $CRISPR $CRISPR is a community driven research DAO focusing on the evolution of open source AI agents and DeSci For everyone's information, CRISPR (Clustered Regularly Interspaced Short
7
15
57
Who’s Truly Leading the Game? 🚀 The largest fundraising project of 2,100 SOL has just landed on Daosfun! 🚀 @daosdotfun ! 🔥 Introducing Nuclease DAO (NuDAO) – The Future of Decentralized Science 🌍🔬 ✅ Funding pioneering DeSci research ✅ Tokenizing research outcomes into
0
2
7
This is fantastic insight. Don’t fade it!
I have been bullish about Decentralized Science (#DeSci) for some time and have been knee-deep in researching them with the @Blockcircle alpha community for quite some time, I have allocated a portion of my portfolio across multiple DeSci projects. #DeSci is not being discussed
0
0
1
These stats clearly outline the result of funding attrition from governments towards academic research. I wouldn’t say academia is a mess, I would say government funding towards research needs correcting. I see DeSci as a potential solution to this.
🚨ACADEMIA IS A MESS: 41% OF POSTDOCS QUIT | WE ARE LEFT WITH THE REJECTS TEACHING OUR KIDS Imagine spending 10 years earning a PhD, then landing a “postdoc” job that pays peanuts and promises no future. Now imagine realizing there are way more postdocs than faculty jobs.
0
0
0
9/ To push boundaries in oncology or any field, we need to support open, decentralised, AND collaborative science. Instead of anti-academia narratives, let's focus on connecting these nodes for even greater impact. 🌍⚙️
0
0
0
8/ Decentralising science means making collaboration easier—not eliminating key players. Academia, biotech, and big pharma each play a role in turning discoveries into therapies. The innovation ecosystem thrives on all its parts.
1
0
0
7/ For DeSci enthusiasts: don’t dismiss academia. Many researchers in this study bridged the gap between academic theory and biotech innovation. Without their early groundwork, most biotechs wouldn’t exist. 🤝
1
0
0
6/ The big surprise? FIC drugs from large pharma see disproportionately high revenues—median sales are 8x higher than small biotech’s. Is this just better marketing? Not quite. It’s about resources for trials, global rollout, and maximising impact.
1
0
0
5/ Large pharma has its strengths too. It may not discover as many drugs, but it shepherds 76% of FIC therapies through clinical development and commercialisation. Without these resources, many biotechs wouldn’t reach patients. 🏥
1
0
0
4/ Take CAR-T therapy (Kymriah) or the prostate cancer drug Zytiga—both groundbreaking. These originated in academia before industry carried them to market. This synergy drives innovation, not just one group alone.
1
0
0
3/ Academia’s role goes deeper than direct discoveries. Many small biotechs are spin-outs from academic labs. 60% of small pharma founders in the study had tenure-track academic backgrounds. Academia isn’t the competition—it’s the foundation. 💡
1
0
0
2/ Small biotech takes the crown for FIC innovation, originating 46% of these cutting-edge therapies. Large pharma, despite its size, lags with only 14%. Academia? It matches large pharma, also at 14%. But the story doesn’t end there.
1
0
0
1/ 🚨 Who drives first-in-class (FIC) innovation in oncology? A recent study explored this question: https://t.co/Fw6HrUNPzF. The findings are fascinating—and bust a few myths about academia's role in drug discovery. #DeSci 🧵👇
1
0
0